1-8 of 8
Ji Wu
Close
Sort by
Journal Articles

Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells

Ji Wu, Feng Meng, Henry Lu, Ling Kong, William Bornmann, Zhenghong Peng, Moshe Talpaz, Nicholas J. Donato
Journal: Blood
Blood (2008) 111 (7): 3821–3829.
https://doi.org/10.1182/blood-2007-08-109330
Published: 2008
Journal Articles

Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells

Geoffrey A. Bartholomeusz, Moshe Talpaz, Vaibhav Kapuria, Ling Yuan Kong, Shimei Wang, Zeev Estrov, Waldemar Priebe, Ji Wu, Nicholas J. Donato
Journal: Blood
Blood (2007) 109 (8): 3470–3478.
https://doi.org/10.1182/blood-2006-02-005579
Published: 2007
Journal Articles

A Novel BCR-ABL Mutation Predicts Resistance to Tyrosine Kinase Inhibitor (TKI) Therapy by a Unique Mechanism in Patients (pts) with Philadelphia-Positive (Ph+) Leukemia.

Alfonso Quintas-Cardama, MD, Jorge Cortes, MD, Hagop M. Kantarjian, MD, Moshe Talpaz, MD, Ji Wu, Feng Meng, Nicholas Donato, PhD
Journal: Blood
Blood (2006) 108 (11): 4773.
https://doi.org/10.1182/blood.V108.11.4773.4773
Published: 2006
Journal Articles

Activity of ABL Kinase Inhibitors in Two Distinct Models of Imatinib Resistance.

Nicholas J. Donato, PhD, Ji Wu, M.D., William Bornmann, Ph.D., Moshe Talpaz, M.D.
Journal: Blood
Blood (2006) 108 (11): 4819.
https://doi.org/10.1182/blood.V108.11.4819.4819
Published: 2006
Journal Articles

Lyn Kinase Alters Gab2 Phosphorylation and c-Cbl Protein Levels To Regulate Imatinib Sensitivity and Survival of Chronic Myelogenous Leukemia Cells.

Ji Wu, MD, Feng Meng, M.D., Moshe Talpaz, M.D., Nicholas J. Donato, PhD
Journal: Blood
Blood (2006) 108 (11): 2132.
https://doi.org/10.1182/blood.V108.11.2132.2132
Published: 2006
Journal Articles

Constitutive Activation of SRC-Family Kinases in Chronic Myelogenous Leukemia Patients Resistant to Imatinib Mesylate in the Absence of BCR-ABL Mutations: A Rationale for Use of SRC/ABL Dual Kinase Inhibitor-Based Therapy.

Nicholas J. Donato, PhD, Ji Wu, MD, Ling-Yuan Kong, MD, PhD, Feng Meng, MD, Francis Lee, PhD, Moshe Talpaz, MD
Journal: Blood
Blood (2005) 106 (11): 1087.
https://doi.org/10.1182/blood.V106.11.1087.1087
Published: 2005
Journal Articles

Targeting BCR-ABL and Its Downstream Signaling Cascade as Therapy for Chronic Myelogenous Leukemia.

Nicholas J. Donato, PhD, Ji Wu, MD, Ling Y. Kong, MD, PhD, Feng Meng, MD, Waldemar Priebe, PhD, Moshe Talpaz, MD
Journal: Blood
Blood (2004) 104 (11): 2964.
https://doi.org/10.1182/blood.V104.11.2964.2964
Published: 2004
Journal Articles

The SRC/ABL Inhibitor BMS-354825 Overcomes Resistance to Imatinib Mesylate in Chronic Myelogenous Leukemia Cells through Multiple Mechanisms.

Nicholas J. Donato, Ph.D., Ji Wu, M.D., Ling Y. Kong, Ph.D., M.D., Francis Lee, Ph.D., Moshe Talpaz, M.D.
Journal: Blood
Blood (2004) 104 (11): 1989.
https://doi.org/10.1182/blood.V104.11.1989.1989
Published: 2004